Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Pharmacokinetic parameters

From: Bioequivalence study of three ibuprofen formulations after single dose administration in healthy volunteers

Parameter analyzed Sequence Treatment Mean SD CV (%) Geometric mean
AUC0-t(last) (μg/ml*h) AE/EA Nurofen® 117.00 31.94 27.3 113.4
   Eudorlin® 119.79 29.04 24.2 116.6
  EB/BE Migränin® 115.21 21.83 19.0 113.1
   Eudorlin® 115.84 22.73 19.6 113.7
AUC0-∞ (μg/ml*h) AE/EA Nurofen® 117.38 32.01 27.3 113.8
   Eudorlin® 120.15 29.07 24.2 117.0
  EB/BE Migränin® 115.57 21.84 18.9 113.5
   Eudorlin® 116.22 22.73 19.6 114.1
Cmax (μg/ml) AE/EA Nurofen® 32.92 8.29 25.2 31.83
   Eudorlin® 36.62 6.16 16.8 36.11
  EB/BE Migränin® 30.87 6.31 20.4 30.25
   Eudorlin® 35.94 6.30 17.5 35.41
t1/2 (h) AE/EA Nurofen® 2.52 0.44 17.6 2.495
   Eudorlin® 2.55 0.42 16.6 2.522
  EB/BE Migränin® 2.50 0.33 13.1 2.478
   Eudorlin® 2.66 0.79 29.8 2.583
    Mean SD CV Median
tmax (h) AE/EA Nurofen® 1.82 1.05 57.9 1.50
   Eudorlin® 1.14 0.67 59.1 1.00
  EB/BE Migränin® 1.78 0.97 54.5 1.75
   Eudorlin® 1.13 0.80 71.1 0.75
  1. Pharmacokinetic data by treatment pair and treatment (Pharmacokinetic population; N = 60). "A" refers to Nurofen® forte, "B" refers to Migränin® and "E" refers to Eudorlin® extra. SD: standard deviation, CV: coefficient of variation.